Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : Statement of Changes in Beneficial Ownership

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 06:29pm EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or

Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading Symbol

BOURLA ALBERT

PFIZER INC [ PFE ]

(Street)

4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

NEW YORK, NY 10017

_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

2. Trans. Date 2A. Deemed

4. Securities Acquired (A) 5. Amount of Securities Beneficially Owned or Disposed of (D)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

(1)

3A. Deemed 4. Trans. Execution

6. Date Exercisable and 7. Title and Amount of Expiration Date

Phantom Stock Units SSP

1/10/2019

(2)

8. Price of 9. Number of Derivative

A

37.0000

(2)

Common Stock

37.0000

$42.3100

12671.0000

D

Explanation of Responses:

  • (1) Each unit represents one phantom share of common stock.

(2)

These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Reporting Owners

Reporting Owner Name / Address

Relationships

Director

10% Owner

Officer

Other

BOURLA ALBERT

PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST.

NEW YORK, NY 10017

X

Chief Executive Officer

Signatures

Susan E. Grant, by power of atty., for Albert Bourla

1/11/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Disclaimer

Pfizer Inc. published this content on 11 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 January 2019 23:28:01 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
06:38aPFIZER : European Commission Approves TALZENNA (talazoparib) for Patients with I..
AQ
06/22PFIZER : Manufacturing of paediatric medicines set to improve with new investmen..
AQ
06/21PFIZER INVESTIGATION INITIATED BY FO : Kahn Swick & Foti, LLC Investigates the O..
BU
06/21PFIZER : European Commission Approves TALZENNA® (talazoparib) for Patients with ..
BU
06/21PFIZER : to Lead a Post-Conference Workshop at Lyophilization USA 2019
AQ
06/20GSK Offers Concessions on Pfizer JV to Quell EU Antitrust Fears
DJ
06/20GLAXOSMITHKLINE : GSK offers concessions to address EU concerns over Pfizer deal
RE
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19CEOs of some U.S. firms to meet Chinese Premier Li this week - Bloomberg
RE
06/18WeissLaw LLP Investigates Array BioPharma Acquisition
PR
More news
Financials ($)
Sales 2019 53 351 M
EBIT 2019 19 750 M
Net income 2019 13 323 M
Debt 2019 26 335 M
Yield 2019 3,28%
P/E ratio 2019 18,16
P/E ratio 2020 16,58
EV / Sales 2019 5,04x
EV / Sales 2020 4,95x
Capitalization 243 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 45,6 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER0.05%233 072
JOHNSON & JOHNSON10.10%348 981
ROCHE HOLDING LTD.13.87%227 848
NOVARTIS21.31%220 893
MERCK AND COMPANY10.68%206 641
ELI LILLY AND COMPANY-0.20%113 364